Allelic imbalance on chromosome 17p13 in borderline (low malignant potential) epithelial ovarian tumors

International Journal of Gynecological Pathology

Volumn 18, Issue 3, 1999, Pages 247-253

  Zanotti, Kristine M ^a   Hart, William R ^a   Kennedy, Alexander W ^a   Belinson, Jerome L ^a   Casey, Graham ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Allelic imbalance; Borderline tumors; Implantation theory of peritoneal spread; Multicentric theory of peritoneal spread; Ovarian cancer; Ovary; Tumor suppressor genes

Indexed keywords

ALLELE; ARTICLE; CHROMOSOME 17P; GENE LOCUS; HUMAN; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0032982236     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199907000-00010     Document Type: Article

References (37)

1. Hart WR. Pathology of malignant and borderline (low malignant potential) epithelial tumors of ovary. In: Coppleson M, Monaghan JM, Morrow CP, Tattersall MHN, eds. Gynecologic oncology, 2nd ed. New York, NY: Churchill-Livingstone, 1992:863-7.
2. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis and transformation to invasive serous carcinoma. Cancer 1996;78:278-86.
3. Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 1973;31:1031-5.
4. Link CJ, Kohn E, Reed E. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. Gynecol Oncol 1996;60:347-4.
5. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-2.
6. Ichikawa Y, Nishida M. Suzuki H, et al. Mutation of K-ras protooncogene is associated with histologic subtypes in human mucinous ovarian tumors. Cancer Res 1994;54:33-5.
7. Ponder BAJ. Gene losses in human tumours. Nature 1988;335:400-1.
8. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, Leonard RC. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992;65:40-4.
9. Foulkes WD, Black DM, Stamp GW, Solomon E, Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 1993;54:220-5.
10. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistological staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
11. Sakamoto T, Nomura N, Mori H, Wake N. Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers. Gynecol Oncol 1996;63:173-9.
12. Phillips NJ, Ziegler M, Saha B, Xynos F. Allelic loss on chromosome 17 in human ovarian cancer. Int J Cancer 1993;54:85-1.
13. Stack M, Jones D, White G, et al. Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3. Hum Mol Genet 1995;4:2047-55.
14. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, Donis-Keller H. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 1996;56:606-11.
15. Wiper DW, Zanotti KM, Kennedy AW, Belinson JL, Casey G. Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers. Gynecol Oncol 1998;71:77-82.
16. Wertheim I, Tangir J, Muto MG, Welch WR, Berkowitz RS, Chen WY, Mok, SC. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors. Oncogens 1996;12:2147-53.
17. Segal GH, Hart WR. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic surface tumor to peritoneal 'implants.' Am J Surg Pathol 1992;16:577-83.
18. Pettersson F. Carcinoma of the ovary. In: Pettersson F, Creasman WT, Shepherd JH, Pecorelli S, eds. Annual report on the results of treatment in gynecological cancer, vol 22. Stockholm: International Federation of Gynecology and Obstetrics, 1993:38-43.
19. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 1990;21:397-403.
20. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas. A clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 1998;22:1449-62.
21. Plummer SJ, Paris MJ, Myles J, Tubbs R, Crowe J, Casey G. Four regions of allelic imbalance on chromosome 17q12-qter associated with high-grade breast tumors. Genes Chromosom Cancer 1997;20:354-62.
22. Wales MM, Biel MA, el Deiry W, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995;1:570-7.
23. Schultz DC, Vanderveer L, Herman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 1996;56:1997-2002.
24. Phillips NJ, Zeigler MR, Deaven LL. A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Cancer Lett 1996;102:85-90.
25. The Utah Marker Development Group. A collection of ordered tetranucleotide-repeat markers from the human genome. Am J Hum Genet 1995;57:619-28.
26. Rodabaugh KJ, Blanchard G, Welch WR, Bell DA, Berkowitz RS, Mok SA. Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors. Cancer Res 1995;55:2169-72.
27. Rodabaugh KJ, Biggs RB, Qureshi JA, et al. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene 1995;11:1249-54.
28. Saretzki G, Hoffmann U, Hohlke P, et al. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 1997;80:1241-9.
29. Chenevix-Trench G, Kerr J, Hurst T, et al. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosom Cancer 1997;18:75-83.
30. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 1995;64:434-40.
31. White GR, Stack M, Samibanez-Koref M, et al. High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. Br J Cancer 1996;74:863-70.
32. Berchuck A, Kohler MF, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994:52:232-6.
33. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-51.
34. Schelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer 1995;72:521-7.
35. Tangir J, Loughridge NS, Berkowitz RS, Muto MG, Bell DA, Welch WR, Mok SC. Frequent microsatellite instability in epithelial borderline ovarian tumors. Cancer Res 1996;56:2501-5.
36. Russell P. Borderline epithelial tumors of the ovary: a conceptual dilemma. Clin Obstet Gynecol 1984;22:259-77.
37. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998;58:2328-30.